{
    "cancer_info": {
        "cancer_name": "Cervical Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Pelvic exam",
            "Colposcopy with biopsy",
            "Cervical biopsy (cone biopsy preferred for fertility-sparing candidates)",
            "Cold-knife cone biopsy",
            "LEEP (Loop Electrosurgical Excision Procedure)",
            "Pathology review (margin status, LVSI, histology, grade, tumor size, depth of invasion)",
            "Ultrastaging of Sentinel Lymph Nodes (SLNs)",
            "CBC (Complete Blood Count)",
            "Platelet count",
            "Renal function tests",
            "Hepatic function tests",
            "HIV testing",
            "HPV testing",
            "Pelvic MRI (for Stage I and fertility-sparing planning)",
            "FDG PET-CT (for Stage IB3-IVA)",
            "CT chest/abdomen/pelvis (alternative to PET-CT)",
            "Chest X-ray (CXR)",
            "Chest CT",
            "Brain MRI (for neuroendocrine carcinoma)",
            "Cystoscopy (if bladder involvement suspected)",
            "Proctoscopy (if bowel involvement suspected)",
            "Examination under anesthesia (EUA) for advanced stages",
            "Sentinel lymph node mapping",
            "Pelvic lymphadenectomy",
            "Para-aortic lymphadenectomy",
            "PD-L1 testing (Combined Positive Score)",
            "MSI-H/dMMR testing",
            "Tumor Mutational Burden (TMB) testing",
            "HER2 testing (IHC/FISH)",
            "NTRK fusion testing",
            "RET fusion testing",
            "Neuroendocrine markers (chromogranin, synaptophysin, CD56)",
            "Smoking cessation counseling"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IA1",
            "risk_group": "No LVSI",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Simple hysterectomy or observation",
                    "plan_details": "Type A hysterectomy or surveillance",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA1",
            "risk_group": "With LVSI",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Conization + lymph node assessment",
                    "plan_details": "Conization with negative margins + pelvic SLN mapping/lymphadenectomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA2-IB1",
            "risk_group": "Fertility-sparing eligible",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Tumor ≤2cm, no LVSI, negative margins",
                    "plan_name": "Radical trachelectomy + SLN mapping",
                    "plan_details": "Laparoscopic/open radical trachelectomy with pelvic lymphadenectomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Meets conservative criteria",
                    "plan_name": "Conization + surveillance",
                    "plan_details": "Cone biopsy with negative margins and negative imaging",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB1-IB2",
            "risk_group": "Non-fertility-sparing",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Radical hysterectomy",
                    "plan_details": "Type B/C radical hysterectomy + pelvic lymphadenectomy (open approach)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB3-IVA",
            "risk_group": "Locally advanced",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Definitive chemoradiation",
                    "plan_details": "Cisplatin (40mg/m² weekly) + EBRT + brachytherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "FIGO 2014 Stage III-IVA",
                    "plan_name": "Pembrolizumab + chemoradiation",
                    "plan_details": "Pembrolizumab added to cisplatin + EBRT + brachytherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Alternative",
                    "patient_subgroup": "Cisplatin-intolerant",
                    "plan_name": "Carboplatin-based chemoradiation",
                    "plan_details": "Carboplatin (AUC 2 weekly) + EBRT + brachytherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative"
                }
            ]
        },
        {
            "staging_criteria": "Post-operative",
            "risk_group": "Intermediate risk (Sedlis criteria)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Node-negative with ≥2 risk factors",
                    "plan_name": "Pelvic EBRT",
                    "plan_details": "External beam radiotherapy alone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Post-operative",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Positive nodes/margins/parametria",
                    "plan_name": "Chemoradiation",
                    "plan_details": "Cisplatin + EBRT",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic or recurrent disease",
            "risk_group": "PD-L1 positive (CPS≥1)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All",
                    "plan_name": "Pembrolizumab + chemotherapy ± bevacizumab",
                    "plan_details": "Pembrolizumab + cisplatin/carboplatin + paclitaxel ± bevacizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic or recurrent disease",
            "risk_group": "All comers",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All",
                    "plan_name": "Platinum-taxane ± bevacizumab",
                    "plan_details": "Carboplatin/cisplatin + paclitaxel ± bevacizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line",
                    "patient_subgroup": "All",
                    "plan_name": "Tisotumab vedotin",
                    "plan_details": "Monotherapy targeting tissue factor",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line",
                    "patient_subgroup": "HER2+",
                    "plan_name": "Trastuzumab deruxtecan",
                    "plan_details": "HER2-directed antibody-drug conjugate",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Small cell neuroendocrine carcinoma",
            "risk_group": "Localized",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Chemoradiation",
                    "plan_details": "Cisplatin + etoposide + EBRT/brachytherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Small cell neuroendocrine carcinoma",
            "risk_group": "Metastatic",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All",
                    "plan_name": "Platinum-etoposide ± immunotherapy",
                    "plan_details": "Cisplatin/carboplatin + etoposide ± atezolizumab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "PD-L1 (CPS≥1): Predicts response to immunotherapy (pembrolizumab/cemiplimab); MSI-H/dMMR: Predicts immunotherapy response; TMB-H (≥10 mut/Mb): Predicts pembrolizumab response; HER2 (IHC 3+ or 2+): Predicts trastuzumab deruxtecan efficacy; HER2 mutation: Predicts neratinib response; RET fusion: Predicts selpercatinib response; NTRK fusion: Predicts entrectinib/larotrectinib response; HPV status: Distinguishes HPV-associated (better prognosis) vs HPV-independent tumors; LVSI: Key prognostic factor affecting management"
    },
    "guideline_id": "（2025.V3）NCCN临床实践指南：宫颈癌.txt"
}